Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK

被引：0
|
作者：
Sophie Beale
Adrian Bagust
Arran T. Shearer
Alan Martin
Lisa Hulme
机构：
[1] University of York,York Health Economics Consortium, Market Square
[2] University of Liverpool,The University of Liverpool Management School
[3] GlaxoSmithKline,UK Health Outcomes
[4] GlaxoSmithKline,Global Health Outcomes
来源：
PharmacoEconomics | 2006年 / 24卷 / Suppl 1期
关键词：
Metformin; National Health Service; Rosiglitazone; Glycaemic Control; Sulfonylurea;
D O I：
10.2165/00019053-200624001-00003
中图分类号：
学科分类号：
摘要：
Introduction: Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant improvements in the control of fasting plasma glucose/glycosylated haemoglobin A1c (HbA1c) after the failure of metformin monotherapy. Our objective was to assess the cost-effectiveness of the use of rosiglitazone in combination with metformin in overweight and obese patients with type 2 diabetes in the UK, failing to maintain glycaemic control with metformin monotherapy compared with conventional care using metformin in combination with sulfonylurea.
引用
收藏
页码：21 / 34
页数：13
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ROSIGLITAZONE COMBINATION THERAPY FOR THE TREATMENT OF TYPE 2 DIABETES IN THE CZECH REPUBLIC
    Dolezal, T.
    Skoupa, J.
    Taylor, M. J.
    Whitehead, S.
    Rausova, V
    Pavlikova, P.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A504 - A504
  • [2] Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany
    Shearer A.T.
    Bagust A.
    Liebl A.
    Schoeffski O.
    Goertz A.
    [J]. PharmacoEconomics, 2006, 24 (Suppl 1) : 35 - 48
  • [3] The cost-effectiveness of pioglitazone in combination with metformin in the treatment of type 2 diabetes mellitus in Scotland
    Stynes, G
    Tilden, D
    Swift, M
    Cockle, S
    Haycox, A
    Aristides, M
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 737 - 738
  • [4] Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
    Lee, W. C.
    Conner, C.
    Hammer, M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 897 - 906
  • [5] Lifetime cost-effectiveness of rosiglitazone/metformin fixed dose combination for the treatment of type 2 diabetes in Portugal
    Taylor, M.
    Shearer, A.
    Bagust, A.
    Vaz, J. P.
    Pereira, J.
    [J]. DIABETES, 2006, 55 : A548 - A548
  • [6] Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain
    Shearer A.T.
    Bagust A.
    Ampudia-Blasco F.J.
    Álvarez B.M.-L.
    Escolano I.P.
    París G.
    [J]. PharmacoEconomics, 2006, 24 (Suppl 1) : 49 - 59
  • [7] Cost-effectiveness in Germany of rosiglitazone-metformin combination in Type 2 diabetes.
    Bagust, A
    Shearer, A
    Schoeffski, O
    Reitberger, U
    Goertz, A
    Behrens, M
    [J]. DIABETOLOGIA, 2003, 46 : A444 - A444
  • [8] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Vega-Hernandez, Gabriela
    Wojcik, Radek
    Schlueter, Max
    [J]. DIABETES THERAPY, 2017, 8 (03) : 513 - 530
  • [9] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    [J]. Diabetes Therapy, 2017, 8 : 513 - 530
  • [10] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Manrique, H.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
12345